These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 23910623)
1. Long-term efficacy and safety of maintenance therapy with azathioprine or cyclosporine for interstitial lung disease with diffuse cutaneous scleroderma. Ando K; Nakashita T; Kaneko N; Takahashi K; Motojima S Clin Exp Rheumatol; 2013; 31(2 Suppl 76):191-2. PubMed ID: 23910623 [No Abstract] [Full Text] [Related]
2. Azathioprine-induced pure red cell aplasia in a systemic sclerosis patient with interstitial pneumonia. Suto M; Nagai Y; Hasegawa M; Handa H; Ishikawa O J Dermatol; 2011 Mar; 38(3):285-7. PubMed ID: 21342234 [No Abstract] [Full Text] [Related]
3. Azathioprine is essential following cyclosporine for patients with steroid-refractory ulcerative colitis. Miyake N; Ando T; Ishiguro K; Maeda O; Watanabe O; Hirayama Y; Maeda K; Morise K; Matsushita M; Furukawa K; Funasaka K; Nakamura M; Miyahara R; Ohmiya N; Goto H World J Gastroenterol; 2015 Jan; 21(1):254-61. PubMed ID: 25574099 [TBL] [Abstract][Full Text] [Related]
4. A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years. Moroni G; Doria A; Mosca M; Alberighi OD; Ferraccioli G; Todesco S; Manno C; Altieri P; Ferrara R; Greco S; Ponticelli C Clin J Am Soc Nephrol; 2006 Sep; 1(5):925-32. PubMed ID: 17699309 [TBL] [Abstract][Full Text] [Related]
5. Clinical experience with pirfenidone in five patients with scleroderma-related interstitial lung disease. Miura Y; Saito T; Fujita K; Tsunoda Y; Tanaka T; Takoi H; Yatagai Y; Rin S; Sekine A; Hayashihara K; Nei T; Azuma A Sarcoidosis Vasc Diffuse Lung Dis; 2014 Oct; 31(3):235-8. PubMed ID: 25363224 [TBL] [Abstract][Full Text] [Related]
6. [Efficacy of ab initio immunosuppressive therapy and steroid-sparing effect in interstitial lung disease associated with antisynthetase antibody syndrome]. Franzolini N; Quartuccio L; De Marchi G; De Vita S Reumatismo; 2007; 59(3):202-8. PubMed ID: 17898879 [TBL] [Abstract][Full Text] [Related]
7. [Immunosuppressive therapy for nephrotic syndrome and strategy for adverse side effects from that therapy]. Takeda Y; Tomino Y Nihon Rinsho; 2004 Oct; 62(10):1875-9. PubMed ID: 15500133 [TBL] [Abstract][Full Text] [Related]
8. [Cyclosporin A therapy in steroid-refractory patients with chronic inflammatory bowel diseases]. Dejaco C; Gasché C; Reinisch W; Moser G; Novacek G; Tillinger W; Vogelsang H; Gangl A Wien Klin Wochenschr; 1998 Sep; 110(16):579-84. PubMed ID: 9782579 [TBL] [Abstract][Full Text] [Related]
9. Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 24-month open label, extension phase, single-centre trial. Gordon J; Udeh U; Doobay K; Magro C; Wildman H; Davids M; Mersten JN; Huang WT; Lyman S; Crow MK; Spiera RF Clin Exp Rheumatol; 2014; 32(6 Suppl 86):S-189-93. PubMed ID: 25152211 [TBL] [Abstract][Full Text] [Related]
15. Twelve-month azathioprine as maintenance therapy in early diffuse systemic sclerosis patients treated for 1-year with low dose cyclophosphamide pulse therapy. Paone C; Chiarolanza I; Cuomo G; Ruocco L; Vettori S; Menegozzo M; La Montagna G; Valentini G Clin Exp Rheumatol; 2007; 25(4):613-6. PubMed ID: 17888219 [TBL] [Abstract][Full Text] [Related]
16. Outcomes of pregnancy and the management of immunosuppressive agents to minimize fetal risks in organ transplant patients. Huynh LA; Min DI Ann Pharmacother; 1994 Dec; 28(12):1355-7. PubMed ID: 7696726 [No Abstract] [Full Text] [Related]